ProPublica is tracking the financial ties between doctors and medical companies.
Nearly every large drug maker based in the United States had at least one academic medical center official on its board, raising questions about their independence.
With more data on relationships between doctors and drug companies soon to be released, here are some ways journalists can use this information.
Research has been seen as less objectionable than other forms of interactions with drug companies, but 10 percent of researchers have multiple ties among the nine companies ProPublica analyzed. That raises questions about doctors’ impartiality.
Pharmaceutical company payments to health care professionals dropped between 2011 and 2012 among most of the companies and categories ProPublica tracks, driven in part by increased transparency as well as blockbuster drugs losing patent protection. Research payments, however, have increased among that group.
As transparency increases and blockbuster drugs lose patent protection, drug companies have dramatically scaled back payments to doctors for promotional talks. This fall, all drug and medical device companies will be required to report payments to doctors.
Drugmaker Cephalon had been required to post its payments to doctors online as part of a lawsuit settlement. After its agreement expired, it removed them from its website.
The sixth-largest drug maker already had begun cutting back on paid speaking, ProPublica’s Dollars for Docs database shows.
The drug maker denies wrongdoing, but the Justice Department and a whistleblower say Novartis used cash and meals to get doctors to prescribe its drugs.
We updated Dollars for Docs last week. Why is updating it so difficult?
New data show drugmakers’ payments to hundreds of thousands of doctors, and some have made well over $500,000.
Details behind our drug company money database.
After a long delay, the U.S. Centers for Medicare and Medicaid Services published final rules for the Physician Payments Sunshine Act, which would bring transparency to financial relationships between physicians and industry.
Charlie Ornstein and Tracy Weber talk about the money docs get from drug companies, and why it matters.
Sens. Baucus and Grassley demand evidence of financial support from the drug industry to nonprofit groups that advocate use of opioid painkillers, including the newly defunct American Pain Foundation.
You can still find some older Allergan payments in ProPublica's Dollars for Docs database, along with data from 11 other drug companies.
Sen. Charles Grassley, R-Iowa, wants to know why an Ohio doctor wrote 54 prescriptions per weekday for the antipsychotic Abilify, while the biggest prescriber of Seroquel wrote an average nine prescriptions per hour.
Continued reporting on the influence of pharmaceutical money on medicine spurred tighter rules at medical schools across the nation.
The annual death toll from overdoses of painkillers has reached almost 15,000, prompting the head of the Centers for Disease Control and Prevention to term it an "epidemic." But the American Pain Foundation continues to claim the risks are overblown. The advocacy group's biggest supporter? The drug industry.
American Pain Foundation board members Scott Fishman and Perry Fine, both physicians, have lectured and authored publications funded by makers of narcotic painkillers. They say the support doesn’t bias them.
The agency responsible for administering health care reform, the Centers for Medicare and Medicaid Services, published proposed rules last night, well after its Oct. 1 deadline.